Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Glucose Homeostasis

In brief

This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly inactivated.

Key facts

Study ID

NCT00947011

Run by

Johns Hopkins University

People needed

12

Starts

2009-03-01

Expected to finish

2010-03-01

Last updated by the study team

2017-07-12

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Hct level of at least 34% for women and 36% for men
• Women of non-bearing potential and women of childbearing potential using adequate contraception
• Serum creatine level of less than 1.7 mg/dl
• Four groups:
• Age 21-45 (BMI between 18.50-24.99) \& (BMI between 30-35)
• Age greater than 65 years (BMI between 18.50-24.99) \& (BMI between 30-35)

You may not qualify if…

• Pregnant and/or lactating females
• Women of childbearing potential not willing to use adequate contraception
• Hct below inclusion criteria
• Serum creatine level greater than 1.8 mg/dl
• Age less than 21 and age between 46-64
• Diabetes mellitus
• BMI less than 18 and BMI greater than 35

Where it is running

• Johns Hopkins Bayview Medical Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.